ArticleTranslational lung cancer research2026
Extremely rare primary tracheal hyalinizing clear cell carcinoma: two case reports.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary tracheal hyalinizing clear cell carcinoma (HCCC) is an exceptionally rare, low-grade malignant epithelial tumor. Its nonspecific respiratory manifestations and overlapping histopathological features with other clear cell neoplasms can delay diagnosis. Molecular alterations involving the Ewing sarcoma breakpoint region 1 ( Case Description: Two women presented with respiratory symptoms caused by primary tracheal tumors. The first patient underwent segmental tracheal resection with end-to-end reconstruction. Histopathological and immunohistochemical findings supported HCCC, and molecular testing identified an Conclusions: Primary tracheal HCCC should be considered in the differential diagnosis of tracheal clear cell tumors. Accurate diagnosis requires integration of histomorphology, immunohistochemistry, and molecular testing for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.